BI
BIVI.US Biovie Inc
- Market cap
- USD 12.5M
- P/E
- -
- P/B
- 1.95x
- ROE
- -343.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is BIVI.US undervalued?
Graham numberThe Graham number of Biovie Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biovie Inc fundamental analysis
No fundamental analysis for Biovie Inc yet.
Biovie Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is …
Full company profileBiovie Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biovie Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229K | -229K | -229K | -229K | -229K | -237K | -267K | -229K | -229K | - | - |
| Operating Income | -1.55M | -2.37M | -2.50M | -2.69M | -138M | -27.3M | -45.1M | -32.2M | -18.1M | -22.7M | -22.6M |
| EBITDA | -1.32M | -2.14M | -2.27M | -2.46M | -129M | -23.7M | -45.7M | -29.0M | -17.0M | -21.9M | -22.4M |
| Net Income | -1.33M | -2.41M | -2.44M | -16.7M | -130M | -26.1M | -50.3M | -32.1M | -17.5M | -22.1M | -22.4M |
| EPS | -186 | -315 | -96 | -338 | -1,050 | -106 | -155 | -71 | -12 | -3.05 | -2.71 |
| Balance Sheet | |||||||||||
| Total Assets | 2.36M | 2.18M | 2.57M | 2.08M | 6.05M | 20.1M | 35.1M | 25.2M | 21.6M | 14.3T | 11.0M |
| Total Liabilities | 1.21M | 2.06M | 443K | 23.6M | 996K | 16.4M | 19.8M | 9.70M | 2.55M | 3.98T | 4.51M |
| Shareholders' Equity | 1.16M | 111K | 2.13M | -21.5M | 5.05M | 3.67M | 15.3M | 15.5M | 19.0M | 10.3T | 6.53M |
| Cash & Short-term Investments | 5.14K | 45.8K | 340K | 37.2K | 4.51M | 18.6M | 33.9M | 23.8M | 17.5M | 8.98T | 7.73M |
| Total Debt | 35.0K | 826K | - | 911K | - | 12.3M | 14.4M | 6.11M | 350K | 275B | 254K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -624K | -621K | -2.50M | -1.63M | -10.5M | -19.0M | -40.3M | -27.9M | -19.0M | -19.0B | -11.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 4.00 | 5.00 | 0.00 | 0.00 |
| Free Cash Flow | -624K | -621K | -2.50M | -1.63M | -10.5M | -19.0M | -40.3M | -27.9M | -19.0M | -19.0B | -11.6M |
| Ratios | |||||||||||
| ROE | -115.0% | -2,170.0% | -114.7% | - | -2,579.0% | -710.6% | -327.6% | -207.1% | -92.3% | 0.0% | -343.4% |
| ROA | -56.3% | -110.9% | -94.9% | -800.3% | -2,154.1% | -129.7% | -143.2% | -127.4% | -81.4% | 0.0% | -203.1% |
| Debt to Equity | 0.03x | 7.43x | - | - | - | 3.34x | 0.94x | 0.39x | 0.02x | 0.03x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biovie Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | USD 369B | 250,083 | - |
| 2024 | USD 886K | 1.96 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 53.6M | 432 | - |
| 2020 | USD 17.1M | 347 | - |
| 2019 | USD 48.7K | 1.92 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jul 7, 2025.
Who owns Biovie Inc
- Insiders 0.49%
- Institutions 22.23%
- Public & others 77.29%
- Shares outstanding 10.7M
- Free float 7.48M
Top funds holding BIVI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 38.3K | 0.44% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 10.9K | 0.13% | 0.00% | Sep 2026 |
| Belfund SICAV Belinvest Equity A USD Acc | 10.0K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 7.98K | 0.09% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 2.83K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding BIVI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 605K | 6.97% | +704.92% | Jun 2026 |
| Diametric Capital, LP | 257K | 2.96% | -30.64% | Jun 2026 |
| Renaissance Technologies Corp | 128K | 1.47% | +88.34% | Jun 2026 |
| Citadel Advisors Llc | 96.0K | 1.11% | +111.85% | Jun 2026 |
| Vanguard Capital Management, LLC | 70.9K | 0.82% | -15.66% | Jun 2026 |
| Geode Capital Management, LLC | 70.8K | 0.81% | -15.97% | Jun 2026 |
| Philadelphia Trust Co | 50.0K | 0.58% | -33.33% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 37.6K | 0.43% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 35.9K | 0.41% | +57.34% | Jun 2026 |
| Springbok Capital Management, LLC | 32.6K | 0.38% | -64.61% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 27.6K | 0.32% | 0.00% | Jun 2026 |
| Northern Trust Corp | 21.8K | 0.25% | +53.78% | Jun 2026 |
| Persistent Asset Partners Limited | 15.0K | 0.17% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 14.2K | 0.16% | -32.97% | Jun 2026 |
| Caprock Group Inc | 11.3K | 0.13% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 5.60K | 0.06% | 0.00% | Jun 2026 |
| UBS Group AG | 2.18K | 0.03% | +36,150.00% | Jun 2026 |
| Tower Research Capital LLC | 2.06K | 0.02% | -72.63% | Jun 2026 |
| PNC Financial Services Group Inc | 1.00K | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 867.00 | 0.01% | +275.32% | Jun 2026 |
Biovie Inc company profile
- Company name
- Biovie Inc
- Ticker
- BIVI.US
- Exchange
- USA Stocks
- Listed since
- May 5, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- June
- Address
- 680 W. Nye Lane, Carson City, NV, United States, 89703
- Phone
- 775 888 3162
- Website
- bioviepharma.com
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Biovie Inc management
8- Mr. Cuong Viet Do M.B.A.President, CEO & Director · born 1966
- Ms. Joanne Wendy Kim CPACFO, Treasurer & Corporate Secretary · born 1955
- Dr. Joseph M. Palumbo M.D.Executive VP of R&D and Chief Medical Officer · born 1960
- Mr. Clarence N. AhlemSenior Vice President of Operations · born 1956
- Dr. Penelope Markham Ph.D.Senior Vice President of Liver Disease & Long COVID Programs · born 1966
- Ms. Denise SmithSenior Vice President of Manufacturing & Development
- Dr. Christopher L. Reading Ph.D.Senior Vice President of Alzheimer's Disease Program · born 1948
- Mr. David MorseSenior VP & Chief Regulatory Officer